New combo aims to outsmart resistant breast cancer
Disease control
Recruiting now
This study compares two treatments for advanced estrogen receptor-positive (ER+) breast cancer that has stopped responding to CDK 4/6 inhibitors. About 297 participants will receive either a combination of capecitabine (chemo) and elacestrant (a hormone-blocking drug) or capecita…
Phase: PHASE2 • Sponsor: Kristina A. Fanucci • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC